POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides potassium ions essential for nerve impulse transmission, muscle contraction, and acid-base balance. Sodium chloride provides sodium ions, which are critical for maintaining extracellular fluid volume, osmotic pressure, and electrochemical gradients.
| Metabolism | Potassium and sodium are not metabolized; they are primarily excreted unchanged by the kidneys. |
| Excretion | Potassium: Approximately 90% renal excretion, 10% fecal. Sodium: Excreted renally, >90% under normal conditions. |
| Half-life | Not applicable as potassium and sodium are endogenous ions; distribution and elimination are rapid and depend on renal function and total body stores. |
| Protein binding | Potassium: Negligible (<2%); sodium: Negligible (<5%). |
| Volume of Distribution | Potassium: 0.5-0.6 L/kg (primarily intracellular); sodium: 0.15-0.3 L/kg (primarily extracellular). |
| Bioavailability | Intravenous: 100%; oral: potassium absorption >90%, sodium absorption nearly complete. |
| Onset of Action | Intravenous: immediate within seconds to minutes; oral: onset varies with gastrointestinal absorption, not clinically relevant for replacement. |
| Duration of Action | Duration depends on ongoing losses and renal function; continuous infusion required for sustained effect. |
Intravenous infusion. Potassium chloride 0.3% (3 g/L) and sodium chloride 0.9%: administer at a rate not exceeding 10 mmol/h (0.75 g/h) of potassium, maximum 200 mmol (15 g) per 24 hours. Dose adjusted based on serum potassium and clinical status.
| Dosage form | INJECTABLE |
| Renal impairment | GFR >50 mL/min: no adjustment. GFR 20-50 mL/min: reduce potassium infusion rate by 50%. GFR <20 mL/min: avoid potassium-containing solutions unless severe hypokalemia and close monitoring. |
| Liver impairment | No specific Child-Pugh based dose adjustments for potassium chloride. Use with caution in severe hepatic impairment due to risk of electrolyte disturbances; monitor potassium levels closely. |
| Pediatric use | IV infusion: 0.5-1 mmol/kg/day of potassium, max rate 0.5 mmol/kg/h. Sodium chloride 0.9% as maintenance fluid: 100-150 mL/kg/day for first 10 kg, then 50 mL/kg/day for next 10 kg, then 20 mL/kg/day thereafter. Adjust based on electrolytes and hydration status. |
| Geriatric use | Initiate at lower end of adult dosing. Typical infusion rate: 5-10 mmol/h of potassium, with frequent monitoring of serum potassium and renal function. Maximum 100 mmol/day initially, titrate slowly. Avoid in patients with impaired renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium and sodium are normal constituents of breast milk. Exogenous administration at therapeutic doses does not significantly alter milk concentrations. The M/P ratio is not applicable as these ions are endogenously regulated. Considered compatible with breastfeeding, but monitor infant for electrolyte disturbances if maternal levels are markedly abnormal. |
| Teratogenic Risk |
■ FDA Black Box Warning
Concentrated potassium chloride solutions (≥2 mEq/mL) must be diluted before use; undiluted administration can cause cardiac arrest. This product contains potassium chloride 0.3% (4 mEq/L) and sodium chloride 0.9% (154 mEq/L) and is a dilute solution, thus not subject to the concentrated solution boxed warning.
| Common Effects | fluid replacement |
| Serious Effects |
["Hyperkalemia","Severe renal impairment with oliguria or anuria","Adrenal insufficiency (Addison's disease)","Concurrent use with potassium-sparing diuretics or ACE inhibitors without careful monitoring"]
| Precautions | ["Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia","Monitor serum electrolytes, renal function, and fluid status during prolonged therapy","Rapid infusion may cause cardiovascular overload or hyperkalemia"] |
Loading safety data…
| POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% is an electrolyte replacement solution. Potassium and sodium are essential ions with no known teratogenic risk when administered at physiological concentrations. No fetal abnormalities have been reported with appropriate use. However, extreme electrolyte imbalances may pose indirect risks. Category C: not shown to be harmful in animal studies, but no controlled human studies. Use only if clearly needed. |
| Fetal Monitoring | Monitor serum potassium, sodium, chloride, and renal function periodically during prolonged therapy. For intravenous administration, monitor vital signs, ECG, and infusion site. In pregnancy, assess for fluid overload or electrolyte imbalances that may affect fetal well-being. Use with caution in preeclampsia or renal impairment. |
| Fertility Effects | No known adverse effects on fertility. Potassium and chloride are essential for cellular function and are not associated with reproductive toxicity at therapeutic doses. |